KAPA Kairos Pharma, LTD.

NYSE kairospharma.com


$ 0.68 $ -0.03 (-4.17 %)    

Thursday, 20-Nov-2025 13:49:40 EST
QQQ $ 588.86 $ -22.78 (-3.72 %)
DIA $ 458.15 $ -8.53 (-1.83 %)
SPY $ 654.75 $ -18.15 (-2.7 %)
TLT $ 89.22 $ 0.23 (0.26 %)
GLD $ 373.20 $ -2.02 (-0.54 %)
$ 0.714
$ 0.73
$ 0.68 x 1,000
$ 0.69 x 1,500
$ 0.69 - $ 0.76
$ 0.40 - $ 3.25
131,090
na
14.43M
$ 0.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 04-15-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safet...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cance...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety...

Core News & Articles

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today an...

Core News & Articles

Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05)...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION